Leadership

We are a mission-driven and multidisciplinary team of physicists, molecular biologists, geneticists, epidemiologists, computer scientists, chemists, clinicians, drug developers, and entrepreneurs focused on the development and application of AI to patient data to radically transform the discovery and development of new drugs, and ultimately change the way we treat and eventually cure diseases.

Isabelle Caffry

Senior Director, Strategy & Corporate Development

Bruce Church, PhD

Chief Mathematics Officer and EVP, Research and Early Development

Joseph F. Donahue

Chief Business Officer

Jean-Michel Gries,PhD

President and Chief Operating Officer

Colin Hill

Chief Executive Officer and Co-Founder

Galina Kislukhin, PhD

Senior Director, Operations and Precision Medicine

Jeanne Latourelle, D.Sc.

Senior Vice President, Precision Medicine

Kenneth Levine

Vice President, People and Culture

Mitchell Rosen, PhD

Director of Software Engineering

Zena Sfeir

Vice President, Marketing

So-Youn Shin, PhD

Senior Director, Precision Medicine

Jerome Windsor

Senior Vice President, Business Development & Strategic Alliances

Board of Directors

John Maraganore, PhD

Chair of Aitia Board of Directors, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments. Former founding CEO and Director of Alnylam

Jan Berger, MD, MJ

President & Chief Executive Officer, Health Intelligence Partners, Vice Chair of Aitia Board of Directors

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Rob Coppedge

President and Chief Executive Officer, Echo Health Ventures

Colin Hill

Chief Executive Officer and Co-Founder

Joel Krikston

Managing Director Venture Investments/Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund

Observer

David W. Miller, PhD

Operating Partner, GHO Capital

Observer

Samantha Palmer, PhD

Managing Director, Amgen Ventures

Observer

Timothy Thompson

Independent Director & Former Chairman and Chief Executive Officer, Aptus Health

Adrian Weller, PhD

Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute

Scientific Advisory Board

coming soon

Our Investors

{"infinite":"true","pause_on_hover":"false","adaptive_height":"false","items":"5","auto_play":"true","speed":"1000","rtl_mode":"false","dots":"false","nav":"false","slides_to_scroll":"1","slides_to_scroll_mobile":"1","auto_play_speed":"1000","draggable":"true","swipe":"true","lazy":"false","carousel_mode":"standard","center_mode":"false","center_mode_padding":"60px","vertical":"false","nav_type":"nav_arrow","items_desktop":"4","items_desktop_small":"3","items_tablet":"2","items_mobile":"1","nav_arrow_type_horizon":"angle_arrow_horizon"}

Isabelle Caffry

Senior Director, Strategy & Corporate Development

Isabelle is Senior Director of Strategy & Corporate Development at Aitia. Prior to joining Aitia, Isabelle was a Director in the Transactions Strategy and Execution practice at EY-Parthenon where she consulted on business continuity for Fortune 100 companies undergoing divestitures. Prior to EY-Parthenon, Isabelle worked at Adimab, an antibody discovery platform company, in their Protein Analytics group where she was responsible for antigen quality control and running and designing developability assays. Isabelle has an MBA from Cornell’s Johnson School of Business, a BE in Chemical Engineering from Dartmouth College, and a BS in Chemistry from St. Lawrence University.

Bruce Church, PhD

Chief Mathematics Officer and EVP, Research and Early Development

Bruce Church is responsible for developing algorithms for REFS and leading projects for the development of new products and technologies. Bruce is a member of the founding team of Aitia.

An expert in statistical physics, machine learning, parallel computing, and causal modeling, Bruce helped develop the original REFS platform. Previously, he spent ten years at Cornell University, developing global optimization methods for computational protein folding, the results of which have been published in several peer-reviewed journals.

Bruce has served as the principal investigator on several major grants, including a $2.5 million award from the Department of Energy. He has served on the Board of Directors for U.S. Rugby and coached the under-23 women’s Northeast rugby team. Bruce received a BS in applied and engineering physics and a PhD in applied physics from Cornell University.

Joseph F. Donahue

Chief Business Officer

Joseph Donahue brings a wealth of expertise to this role, having served in a number of senior leadership and Board positions in life sciences and healthcare organizations throughout his career, including at Accenture, BioReference Laboratories, Genospace, LION Bioscience, Medidata Solutions, Monocl, Spotfire, and Thomson Reuters. Mr. Donahue has excelled at building teams to support Life Sciences organizations with technology and data solutions that lead to novel scientific and business insights and have helped accelerate the discovery, development, and commercialization of new medicines.

Jean-Michel Gries, PhD

President and Chief Operating Officer

Jean-Michel Gries is the President and Chief Operating Officer of Aitia. Previously President of Hengenix Biotech, and the Head of Research for Henlius Biotech. His responsibility were in shaping the pipeline and research strategy and establishing the ex-China organization. He joined from Kodikaz Therapeutics, a novel non-viral gene therapy company focusing on oncology, where he was the Chief Research and Development Officer. In that capacity, he supported fund raising for the organization, built the research team and developed and implemented the research strategy. Jean-Michel is an accomplished drug development executive. Starting as a director of clinical pharmacology at Aventis (and predecessor companies), he then became the Head of Clinical Pharmacology for Hoffmann-La Roche. He joined Alcon as the Head of R&D for the Pharmaceutical Products Division, in which capacity he led the transformation of the organization to support more innovative mechanism of actions for the treatment of ocular diseases, leading all activities from research to registration. His successes in the drug development space cover both early stage (with over 275 INDs) and late stage (15+ NDAs, 7 ANDAs) and are a testament both of his strong scientific education, and his focus on driving projects forward.

As a business executive, Dr, Gries helped create 9 companies (2 of which are now public) via 26 assets acquisition and led them early on, in a Venture Capital company specialized in the creation and incubation of Biotechnology startups. He has extensive licensing experience from both Roche (member of the licensing committee) and Aventis (Oncology and CNS licensing committee) and Alcon (Board level). Dr. Gries also served on private companies and Not for Profits Boards of Directors.

Dr. Gries has had exposure over a broad set of disease area, Oncology, Inflammation & Pain, CNS, Metabolism, Cardio-Renal, Anti-Infectives (including HIV and HCV), Dermatology, Ophthalmology, Genito-Urinary, Gastro-Enterology. Dr. Gries joined Covance in 2012 as the General Manager for Early Clinical Development, an organization dedicated to help companies achieve their major clinical and investment decision through efficient Proof of Concept or in-patient studies. He built and grew this organization to a very successful business, winning 3 Business Unit of the Year Award. In 2016, Dr Gries joined Parexel International as the General Manager and Strategic Business Unit Leader of its Early Phase Organization, aka the translational medicine arm of Parexel, to lead its transformation. This organization grew over 26% during his tenure.

Dr. Jean-Michel Gries has a PharmD, and a PhD in pharmacokinetics from Rene Descartes University in Paris, a Master in Statistics and a doctoral degree in Analytical Chemistry. He is a Clinical Pharmacology fellow with numerous assignments both in adult and pediatric medicine and a post-doctoral fellowship from UC San Francisco. He also completed a MBA with a Major in Finance and concentration in entrepreneurial Leadership from the Wharton School.

Dr. Gries is the author of more than 30 papers and communications. He has been a fellow of the American College of Clinical Pharmacology since 2001, served on its Finance Committee and on its Board of Regents, and is a reviewer for JCP. He is also a long-time member of ASCPT and was Member of its Board of Director. Jean-Michel is also a long-term member of ASCO.

Colin Hill

Chief Executive Officer and Co-Founder

Colin Hill is a leading voice in AI and precision medicine and brings impressive leadership experience in developing and commercializing AI solutions and discoveries in biopharmaceutical drug discovery and development and in managed care industries. Colin currently serves on the board of Centrexion Therapeutics, a biotech company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs.

Colin previously served on the boards of Biotelemetry Inc. (NASDAQ: BEAT), the leading mobile health information company (acquired by Philips in 2021), and PPD Inc. (NASDAQ: PPD), a leading global contract research organization (acquired by Thermo in 2021), and was a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014).

He was also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation (501c3) dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Governor Charlie Baker to the Massachusetts Digital Health Council. Colin was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry. In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.

He is a frequent speaker at national and international scientific and industry conferences and has appeared in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call & SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.

He graduated from Virginia Tech with a degree in physics and earned Master’s degrees in physics from both McGill University and Cornell University.

Galina Kislukhin, PhD

Senior Director, Operations and Precision Medicine

Galina is the Senior Director of Operations on the Precision Medicine team. Galina came to Aitia after seven years of work in data science across various industries. Galina has background experience in building and developing teams of scientists and engineers in different environments. Prior to Aitia, she was a key contributor on a product that was recognized as the 2016 Cool Vendor in the project portfolio management space by Gartner. Her contribution in the space of predictive modeling was instrumental in winning this recognition. She holds a Ph.D. in Genetics from University of California, Irvine, a B.S. in Aerospace Engineering and a B.A. in Environmental, Population, and Organismic Biology from CU Boulder. In addition to her professional accomplishments, Galina has a passion for writing science fiction novels. Her debut novel, "Leobela," is currently in the process of being published.

Jeanne Latourelle, D.Sc.

Senior Vice President, Precision Medicine

Jeanne Latourelle heads the Precision Medicine team at Aitia. Prior to Aitia in 2015, Jeanne was at the Boston University School of Medicine where she gained over 10 years of experience in NIH-funded academic research, specifically in the field of genetic epidemiology. Her areas of research included statistical genetics of complex disease, with a focus on neurodegenerative disease and pulmonary function. She has co-authored over 40 papers, including high impact publications in Nature, the New England Journal of Medicine, the Journal of the American Medical Association and Lancet Neurology.

Jeanne holds a BS in biomedical engineering from Boston University, a MS in Mechanical Engineering from MIT and a DSc of Epidemiology from Boston University School of Public Health.

Kenneth Levine

Vice President, People and Culture

Kenneth is Vice President people and culture at Aitia. Prior to that Aitia, Ken was the Vice President of Human Resources for ORIG3N Inc, a Biotechnology company that specializes in DNA testing and regenerative medicine. Prior to ORIG3N Ken was the VP of HR for Skyword Inc., a company that developed proprietary software to enhance Content Marketing for its customers. He has worked at multiple start-up companies including CambridgeSoft that created an electronic notebook (ELN) for the Pharma Industry. Ken was part of the senior team that merged CambridgeSoft and 2 other companies into the PerkinElmer Informatics group where he led the HR function for the $150 million-dollar division. Ken has consulted to multiple software, biotech and technology companies over the years and was the VP of HR for an incubator that launched software security companies.

Kenneth graduated from Bridgewater State University with a BS in Education.

Mitchell Rosen, PhD

Director of Software Engineering

Mitchell Rosen has been at Aitia since 2017 where he is Director of Software Engineering. Mitch came to Aitia after nine years working in medical data simulation at ADI, LLC and other large data projects including OCR and OMR Quality Assurance for the 2010 US Census. Mitch was a Research Professor and Research Scientist in the Center for Imaging Science at RIT where he published and performed research in image quality and spectral imaging. He was a scientist at Polaroid in the 1990’s helping the industry realize high quality consumer color digital imaging systems. He holds a BS in Computer Science from Tufts University and a PhD in Imaging Science from RIT.

Zena Sfeir

Vice President, Marketing

Zena is Vice President of Marketing at Aitia. Prior to joining Aitia, Zena was the co-founder and managing partner of a digital health platform, delivering innovative interactive model between doctors and patients. Taking the company from seed to series B funding and serving millions of patients across 27 countries. Prior to her entrepreneurship venture, Zena led marketing teams at AstraZeneca in Europe and emerging market. In addition to her professional accomplishments, Zena serves on the board of directors of the French Tech Boston, the Pistoia Alliance, and is the co-founder and producer of Spreadloveio.com podcast, partially funded by MIT Sandbox. Zena holds a Marketing Management and Digital Strategy degree from Harvard University, an MSC in Marketing from IAE Poitier, France, and a BS in Business and International Management.

So-Youn Shin, PhD

Senior Director, Precision Medicine

So-Youn leads a neuro team at Aitia to identify novel therapeutics for neurodegenerative diseases. Prior to Aitia, she worked as a research fellow at the Wellcome Trust Sanger Institute and the University of Bristol, where she published over 40 articles in Nature, Nature Genetics and others. She received her graduate degrees from Stony Brook University (M.S. and Ph.D. in Applied Mathematics and Statistics) and bachelor's from Seoul National University.

Jerome Windsor, PharmD

Senior Vice President Business Development & Strategic Alliances

Jerome Windsor, PharmD, is a biopharma senior leader with broad experience building and growing corporations for payers, pharmaceutical, and digital health companies. He specializes in developing and marketing disruptive technologies at the edge of digital, computer sciences, biology, and pharmacology supporting small and large organizations on both strategy and execution sides. Previously, Jerome was Chief Strategy Officer at Celata Bioinnovations, a venture backed spinout from MIT that operates in machine learning applied to protein regulation pathways and was an advisor to a roster of health-tech ventures. Earlier in his career, Jerome led the global commercial activities of Median Technologies, a digital health imaging company specialized in oncology. Under his tenure, the company pivoted its strategy, built its operations in the US, EU, Japan and China, and increased revenue 20x, providing its radiomics technologies and services to most of the top 10 biopharma companies to better diagnose and treat cancer patients. Prior to this, Jerome was Vice President at i3, a UnitedHealth Group company, a Consultant at Accenture and PwC, and Marketing Product Manager at GSK. Jerome is also a Board Member of the French Tech Boston and a mentor at MassBio, a not-for-profit biotechnology trade association that represents and provides support for the Massachusetts life sciences industry. Jerome earned his PharmD from the University of Normandy and his graduated from ESSSEC Business School in Paris (MBA) and the Wharton Business School (EDP).

John Maraganore, PhD

Aitia Chair of the Board of Directors, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments. Former founding CEO and Director of Alnylam.

Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO^®, GIVLAARI^®, OXLUMO^®, and Leqvio^®. At Alnylam, he also led the company’s value creation strategy, building $25B in market capitalization and forming over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he served in leadership, managerial, and scientific roles at Millennium Pharmaceuticals, Biogen, Zymogenetics, and The Upjohn Comoany. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, and Senior Advisor for Blackstone Life Sciences. He is also member of the Board of Directors of publicly traded companies (Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, and Takeda), private companies (Aerium, Hemab, TranSend, and Versanis), and the Biotechnology Industry Organization, where he was Chair from 2017-2019 and is Chair Emeritus. In addition, he serves on the Board of the Termeer Foundation, Chair of the n-Lorem Foundation Advisory Council , and on the Advisory Board of Ariadne Labs. John also serves as a strategic advisor to a number of innovative biotechnology companies, with a focus on mentoring CEOs in their mission to advance science and innovation for patients.

Jan Berger, MD, MJ

President & Chief Executive Officer,Health Intelligence Partners

Vice Chair of Aitia Board of Directors

Jan founded Health Intelligence Partners six years ago as a health care consultancy that blends more than thirty years of business and clinical experience. Health Intelligence Partners has a global focus, working with clients on both short -term and long-term healthcare business strategies and solutions. Jan and Health Intelligence Partners help clients navigate the healthcare environment in order to identify and articulate value opportunities. A great deal of Jan’s focus is on consumer engagement and how it affects the decisions that the consumer makes and the actions that they take.

Prior to founding Health Intelligence Partners, Jan served as Senior Vice President and Chief Clinical Officer for CVS Caremark. During that time, she had Executive Management, P & L, Operations, Innovation and Strategy responsibilities. Before going to CVS Caremark, Jan had 15 years’ experience in healthcare administration within the health plan and academic arenas and lead operations for two population health companies.

As a veteran healthcare executive, Jan’s leadership has delivered results in a variety of settings. Jan offers her experiences and insights through her consulting agency as well as through her participation on healthcare and consumer product boards. She presently sits on healthcare focused boards including AccentCare (Chair; Compliance Committee, Compensation Committee), Aitia, The University of Arizona School of Pharmacy, Harvard Patient Safety Board, Midwest Business Group on Health and Population Health Alliance (Chair: Government Affairs Committee). Jan’s consumer focused boards include Meals to Heal and Whiskerdocs. Jan previously sat on two boards; Care Core National (Committees: Chari: Finance Past Chairperson, Compensation, Search, M&A and Strategic Directions) and Rx-Ante, which were recently sold. She also sits on numerous business and healthcare committees.

As the author of the books “Leveraging Health” and “Thirteen Common Pitfalls in Consumer Engagement” and “Medical Liability for Pediatricians”, the Editor in Chief of American Journal of Pharmacy Benefit and on the editorial boards of a number of healthcare journals, Jan is considered a national health care thought leader. Jan speaks and writes on a broad range of health care issues.

Jan holds both a Doctor of Medicine degree and a Master’s degree in Jurisprudence from Loyola University in Chicago and a Certificate in Healthcare Business Administration from University of South Florida. She also holds a black belt in Six Sigma. Jan is an assistant professor at Northwestern University School of Medicine in Chicago, Illinois.

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Board Member

Craig is responsible for driving business growth via inorganic means. This includes the sourcing and execution of minority investments, joint ventures, and strategic partnerships.

In his current role, Craig leads the investment strategy for Cigna Ventures, Cigna's corporate venture capital fund, which deeply partners with entrepreneurs that are unlocking new growth possibilities in health care. The fund operates to further accelerate Cigna's mission to make healthcare more affordable, predictable, and simple while continuously incubating transformative innovation across three strategic areas: digital health/consumer experience, insights, and analytics, as well as care delivery/enablement.

Craig received a Bachelor of Arts from Gettysburg College and a Master of Health Administration from Cornell University.

Rob Coppedge

Chief Executive Officer, Echo Health Ventures

Board Member

As CEO of Echo Health Ventures, Rob leads the company’s efforts to identify, invest in and grow innovative companies that enable and deliver a transformed experience to health care consumers nationwide. As part of Echo’s unique partnership with its parents, Rob works closely with the senior management teams and board of Cambia Health Solutions and Mosaic Health Solutions to support collaboration with Echo’s portfolio companies, accelerate Cambia and Mosaic’s strategies and more quickly bring health care innovation to national scale. Rob has more than 20 years of experience in health care venture capital and business building. Before founding Echo, Rob served as the President of Cambia Health Solutions’ diversified business unit (Direct Health Solutions). In this role, Rob oversaw Cambia’s wholly-owned operating companies (including cost and quality transparency market leader HealthSparq; ancillary benefits provider LifeMap) as well as its venture and private equity investing activities. Rob joined Cambia in 2010 to launch and build the company’s diversification and corporate venture investment efforts. Under Rob’s leadership, Cambia invested in nearly 20 companies. In 2015, Rob cofounded the Cambia Grove – an innovation hub focused on catalyzing and supporting the Pacific Northwest’s emerging health care economic cluster. At the Cambia Grove, innovators and entrepreneurs work closely with regional stakeholders to find solutions to pressing health care challenges. Before joining Cambia, Rob was the founding partner of Faultline Ventures, where he worked with numerous early stage companies and strategic investors. Previously, he was a Partner at Capitol Health Partners, a Washington, D.C., and New York City-based venture capital firm specializing in early-stage health services and health care information technology. Active in industry and community organizations, Rob serves on the boards of several health care companies and is a founder and former director of the Nashville-based largest network of young health care executives, Leadership Health Care. Rob also serves on the board of directors at Life Science Washington (formerly Washington Biotechnology & Biomedical Association) and the Oregon Museum of Science and Industry (OMSI) and is a member of the American Leadership Forum. Rob is a graduate of Georgetown University with a degree in history and is a Chartered Financial Analyst, charter holder.

Joel Krikston

Managing Director Venture Investments / Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund Board Observer

Joel Krikston is Managing Director Venture Investments and Head of Strategic Innovation Alliances. Joel is focused on identifying new investment opportunities with a focus on Oncology, Vaccines and Infectious Disease. Mr. Krikston has over 20 years of experience in healthcare innovation. Prior to joining Merck GHI, he was an Investment Principal at Johnson & Johnson Development Corporation. Joel also spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro. Joel has an MBA from the Stern School of Business at NYU and completed his Bachelor’s degree in Finance and International Business at Fairfield University.

David W. Miller, PhD

Operating Partner, GHO Capital Board Observer

Dave is an accomplished global pharmaceutical executive and advisor with over 25 years of experience. He is an Operating Partner at GHO Capital, focusing on health care investments. He also operates a specialty advisory practice, advising pharmaceutical executives on pricing, access and health economic and outcomes research strategies. From 2010 to 2017, he was Senior Vice President of Global Market Access at Biogen. He previously worked at Elan, holding roles as Vice President of Pharmacoeconomics and Managing Director. Dr. Miller began his pharmaceutical industry career at GlaxoSmithKline in pharmacoeconomics and assumed increasing responsibilities towards becoming Vice President of Global Health Outcomes. A dual US/UK citizen, he has lived and worked in Europe, Asia and the US. Dr. Miller is the author or co-author of over 70 scientific publications. He is a member of advisory boards at the University of Maryland Baltimore, the University of Washington and Tufts University, and a board member of the Walther Foundation, a charitable organization supporting youth education in the San Francisco Bay Area. He previously served on the Board of Directors of Elan Pharma Ltd and the National Pharmaceutical Council, and was Chair of the Board of Grants for the American Foundation for Pharmaceutical Education. He holds a degree in pharmacy from the University of Iowa and earned his PhD in pharmacy administration at the University of Maryland Baltimore, where he studied health economics and policy.

Samantha Palmer, PhD

Managing Director, Amgen Ventures

Samantha joined Amgen, Inc. in 2015 and is the Managing Director of Amgen Ventures where she directs investments in biopharmaceutical and digital technology companies. She currently serves as a board observer for several portfolio companies including Curate Biosciences and Aetion. She served as an interim Board Observer while Senti Biosciences was finalizing its SPAC merger in 2022. Prior to joining Amgen Ventures, Samantha served as the Chief of Staff and Strategic Planning and Operations Lead for the Office of the CEO and before then was the Business Development Search and Evaluation Lead for the Inflammation Therapeutic Area where she finalized several deals including the asset acquisition of Otezla – approved oral PDE4 small molecule inhibitor for the treatment of psoriasis. Prior to joining Amgen, Samantha was the first employee at Innovimmune Therapeutics where she held Corporate Development and Principal Scientist positions. Samantha earned her PhD in Immunology and Microbial Pathogenesis from Cornell University and an MBA from The Wharton School, University of Pennsylvania.

Timothy Thompson

Independent Director, Former Chairman and Chief Executive Officer, Aptus Health

Timothy Thompson is the former Chairman and CEO of Aptus Health, a global digital health company whose core platform, Univadis®, delivers medical news, thought leader education, and conference coverage to over four million healthcare professionals around the world. A wholly owned subsidiary of Merck & Co., Aptus Health was acquired by WebMD in 2019. Mr. Thompson currently serves as independent director on the board of Aitia and as an advisor to Echo Health Ventures.

Prior to Aptus Health, Mr. Thompson served as the Chairman and CEO of Intervention insights, a health information services company supporting evidence-based care in molecular oncology. Prior to Intervention Insights, Mr. Thompson served as the President and CEO of Proventys, an innovative healthcare technology company that developed web-based decision support solutions in oncology. Before joining Proventys, Mr. Thompson was a business development executive at Aetna, Inc., serving as Managing Director of mergers & acquisitions and the Head of Strategic Business Development for Aetna Health Information Solutions.

Earlier in his career, Mr. Thompson served as the Chief Operating Officer and Vice President of Business Development for PHT Corporation, a privately held mobile data capture and clinical trial software company. He joined PHT after successfully negotiating the sale of Clinical Data Solutions, Inc. where he had been founder and CEO.

Mr. Thompson received a BA in Zoology and Biochemistry from the University of New Hampshire where he was elected into the Phi Beta Kappa honor society.

Adrian Weller, PhD

Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute Board Member

Adrian is a Senior Research Fellow in the Machine Learning Group at the University of Cambridge, in the Computational and Biological Learning Lab, and also serves as a Faculty Fellow at The Alan Turing Institute, the United Kingdom’s national institute for data science. Most of his academic research relates to graphical models, but he is also very interested in other areas including finance, anything on intelligence (natural or artificial), deep learning, reinforcement learning, evolution, Bayesian methods, time series analysis, ethics, music and methods for big data.

Prior to his current roles, Adrian served as a Managing Director at Citadel Investment Group where he ran US and European interest rate trading. Earlier, Adrian was in the fixed income proprietary trading group at Salomon Brothers, and previously ran the fixed income options desk at Goldman Sachs.

Adrian completed his PhD in Computer Science from Columbia University, and holds a BA and MA in Mathematics from Trinity College, Cambridge. He is an active angel investor, board member and advisor to many companies and charities apart from Aitia, including Simplex, Cambridge in America, and the Coexist Foundation.